admin
- The landmark presentation titled “Successful Development of a Pharmacological Concept to Treat Cerebral Stroke Patients” highlighted the company’s lead asset, Sovateltide an innovative endothelin-B agonist
- Since its approval and market launch in September 2023, Sovateltide has successfully treated over 50,000 patients in India
India
healthysoch
New Delhi, November 29, 2024:
Pharmazz, Inc., a late-stage biopharmaceutical company addressing the critical care market, showcased the groundbreaking potential of its lead drug, Sovateltide, at the International Pharmacology Conference & 54th Annual Conference of Indian Pharmacological Society (IPC-IPSCON 2024). Organized by the Department of Pharmacology at AIIMS, New Delhi, on November 29, this prestigious event featured an oral presentation by Dr. Anil Gulati, Chairman and Chief Executive Officer of Pharmazz, Inc., Willowbrook, Illinois, USA. His session, titled “Successful development of a pharmacological concept to treat cerebral stroke patients,” highlighted pivotal Phase 3 trial results from India.
Sovateltide, an endothelin-B agonist and first-in-class drug for acute cerebral ischemic stroke, demonstrated statistically significant improvements in neurological outcomes. In a double-blind, placebo-controlled, multicenter Phase 3 clinical trial conducted in India, participants treated with Sovateltide showed a higher proportion of modified Rankin Scale (mRS) scores of 0–2 at 90 days compared to the control group. The overall shift in mRS and National Institutes of Health Stroke Scale scores indicated favorable outcomes for Sovateltide recipients. These findings, which reflect the drug’s safety and efficacy, have been published in a peer-reviewed journal (Gulati et al., 2024 Drugs, PMID: 39542995).
Reflecting on the presentation, Dr. Anil Gulati shared his insights, stating, “Our research represents a significant milestone in stroke treatment. Sovateltide offers hope to millions of patients worldwide by providing a targeted therapeutic approach that addresses the complex neurological challenges associated with cerebral ischemic stroke. We are committed to advancing medical science and improving patient care through innovative pharmaceutical solutions.”
With regulatory approval in India, Sovateltide has already been launched, positively impacting over 50,000 patients since September 2023 through Pharmazz’s strategic partner. Preparations are underway for a larger multinational Phase 3 trial, marking a significant step in advancing treatment options for cerebral ischemic stroke on a global scale.
Pharmazz remains committed to developing innovative therapies for underserved areas of critical care. Its pipeline includes two approved drugs in India and two Phase 3-ready programs in the United States, reinforcing its position as a leader in transforming patient outcomes.
HealthySoch
